STAT Madness 2026: Vote for the Top Biomedical Research | STAT News

March has arrived, and with it, the return of STAT Madness – our annual, bracket-style competition spotlighting the most impactful biomedical research of the past year. Voting is officially open, offering a chance to weigh in on the innovations shaping health and medicine. Cast your vote here and follow along as the field of 64 narrows down.

This year’s competition includes research from institutions across the country, judged on originality, scientific rigor, and potential impact. The innovations nominated were published in 2025, and the bracket is designed to mimic the excitement of the NCAA’s March Madness basketball tournament. Learn more about STAT Madness and its history.

The Landscape of Biomedical Innovation

The annual STAT Madness tournament provides a snapshot of the breadth and depth of biomedical research currently underway. While the specific contenders for 2026 are now set, the broader field of biotech continues to evolve rapidly. Recent developments span gene editing technologies, like those from companies such as Intellia and UniQure, and ongoing efforts to refine healthcare access and affordability, including pilot programs related to Medicaid.

The intersection of these areas – cutting-edge science and real-world healthcare delivery – is particularly noteworthy. Gene editing holds immense promise for treating and potentially curing genetic diseases, but its accessibility and affordability remain significant hurdles. Medicaid, as a key component of the US healthcare system, plays a crucial role in ensuring access to care for millions of Americans. Pilot programs are often used to test new approaches to Medicaid coverage and delivery, aiming to improve outcomes and reduce costs.

Gene Editing Advances: Intellia and UniQure

Companies like Intellia and UniQure are at the forefront of gene editing research, utilizing technologies like CRISPR-Cas9 to precisely target and modify DNA. CRISPR-Cas9 functions as a molecular “scissors,” allowing scientists to cut DNA at specific locations, potentially correcting genetic defects. The National Human Genome Research Institute provides a detailed overview of CRISPR technology.

Intellia, for example, has been developing therapies for transthyretin amyloidosis (ATTR), a rare and often fatal disease caused by a buildup of abnormal protein in various organs. Their approach involves using CRISPR to disable the gene responsible for producing the faulty protein. UniQure focuses on gene therapies for neurological disorders, including Parkinson’s disease. These therapies aim to deliver a functional copy of a missing or defective gene to the brain, restoring neurological function.

However, gene editing technologies are still relatively new, and several challenges remain. Ensuring the precision of gene edits is crucial to avoid unintended consequences, known as “off-target effects.” Delivering gene editing tools to the correct cells and tissues can also be difficult. The long-term effects of gene editing are not yet fully understood, requiring ongoing monitoring and research.

Medicaid Pilots: Expanding Access and Improving Care

Medicaid plays a vital role in providing health coverage to low-income individuals and families. States are continually exploring innovative ways to improve Medicaid programs through pilot initiatives. These pilots often focus on addressing specific health challenges, such as chronic disease management, maternal health, and behavioral health.

One common approach is to implement value-based payment models, which reward healthcare providers for delivering high-quality, cost-effective care. Another strategy is to expand access to telehealth services, particularly in rural areas where access to traditional healthcare is limited. Some states are also experimenting with “health homes,” which provide coordinated care for individuals with complex health needs.

The success of Medicaid pilots depends on careful evaluation and data analysis. Researchers need to assess whether the interventions are actually improving health outcomes and reducing costs. It’s also important to consider the equity implications of these programs, ensuring that they benefit all populations equally. The Centers for Medicare & Medicaid Services (CMS) provides data and resources on Medicaid and CHIP.

Evaluating Pilot Program Effectiveness

Assessing the impact of Medicaid pilot programs requires robust methodologies. Researchers typically employ randomized controlled trials (RCTs) or quasi-experimental designs to compare outcomes between participants in the pilot program and a control group. Key metrics include healthcare utilization rates, hospital readmission rates, and patient-reported outcomes. However, it’s important to acknowledge the limitations of these studies. RCTs can be expensive and time-consuming, and it may be difficult to recruit a representative sample of participants. Quasi-experimental designs are more feasible but may be susceptible to bias.

The Interplay of Innovation and Access

The convergence of scientific advancements like gene editing and healthcare access initiatives like Medicaid pilots presents both opportunities and challenges. If gene editing therapies prove safe and effective, ensuring their affordability and accessibility will be paramount. Medicaid could play a critical role in covering these therapies for eligible patients, but the high cost of these treatments could strain state budgets.

equitable access to gene editing therapies is a major concern. Historically, marginalized communities have been underrepresented in clinical trials, raising the possibility that these therapies may not be equally effective for all populations. Addressing these disparities will require proactive efforts to engage diverse communities in research and ensure that gene editing therapies are available to all who could benefit.

Looking Ahead: Ongoing Research and Policy Considerations

The field of biomedicine is constantly evolving, and ongoing research is essential to address unmet medical needs. STAT Madness serves as a valuable platform for highlighting these advancements and fostering public engagement in science. As new discoveries emerge, policymakers will need to consider their implications for healthcare access, affordability, and equity.

Further research is needed to refine gene editing technologies, improve Medicaid programs, and address the complex interplay between innovation and access. Continued monitoring of clinical trial data, evaluation of pilot program outcomes, and ongoing dialogue between scientists, policymakers, and the public will be crucial to shaping the future of healthcare.

The STAT Madness bracket offers a fun and engaging way to stay informed about the latest breakthroughs in biomedical research. Be sure to vote for your pick and follow the competition as it unfolds.